Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A
スポンサーリンク
概要
- 論文の詳細を見る
- 2009-04-01
著者
-
Ohmi Takashi
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
KOJIMA Midori
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
KATO Naoto
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
HIRANO Daisuke
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
OCHI Takashi
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
NII Aisuke
Drug Safety Research and Development ; Global Research and Development, Nagoya Laboratories, Pfizer
-
SHINJO Katsuhiro
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
EDA Hiroyuki
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
Hirano Daisuke
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Shinjo Katsuhiro
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Kato Naoto
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Nii Aisuke
Drug Safety Research And Development ; Global Research And Development Nagoya Laboratories Pfizer Ja
-
Eda Hiroyuki
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Eda Hiroyuki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Kojima Midori
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Ochi Takashi
Discovery Biology Nagoya Laboratories Pfizer Global Research And Development
-
Nii Aisuke
Drug Safety Research & Development Nagoya Laboratories Pfizer Global Research And Development
関連論文
- Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model
- Erythroderma and Epidermal Necrosis Induced by a Type of Proton Pump Inhibitor in Beagle Dogs
- Contribution of Active and Inactive States of the Human 5-HT_ Receptor to the Functional Activities of 5-HT_4-Receptor Agonists
- Neuronal Necrosis in a Dog Following Exposure to an NMDA Receptor Antagonist
- Anti-PDGF-B monoclonal antibody reduces liver fibrosis development
- Neuronal Necrosis in a Dog Following Exposure to an NMDA Receptor Antagonist
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against .ALPHA.-Fas-Induced Liver Injury in a Mouse Model